Answers are grounded in this paper and cite their sources.
When CODAC Behavioral Healthcare, the main provider of treatment services for corrections in Rhode Island, looks at its clientele with opioid use disorder (OUD), Vivitrol (depot naltrexone) is preferred by no one. The patients want either methadone or buprenorphine, CODAC CEO Linda Hurley explained in a webinar this month (for the first part of this two‐part article, see ADAW ( https://onlinelibrary.wiley.com/doi/10.1002/adaw.34254 ).
No takes yet. Share an insight, caveat, or question.
Alison Knopf (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: